Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2008-09-23
2008-09-23
Nickol, Gary (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S085100, C424S085200, C424S184100, C435S004000, C435S006120, C514S04400A
Reexamination Certificate
active
11635960
ABSTRACT:
Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23.
REFERENCES:
patent: 7090847 (2006-08-01), Oppmann et al.
patent: 7183057 (2007-02-01), Benson
patent: 2003/0083231 (2003-05-01), Ahlem et al.
patent: WO 99/60127 (1999-11-01), None
patent: WO 00/55204 (2000-09-01), None
patent: WO 01/46420 (2001-06-01), None
patent: WO 01/85790 (2001-11-01), None
patent: WO 02/078729 (2002-10-01), None
patent: WO 02/102411 (2002-12-01), None
patent: WO 2004/042009 (2004-05-01), None
patent: WO 2004/060291 (2004-07-01), None
patent: WO 2005/010044 (2005-02-01), None
Teunissen et al., J Invest Dermatol Oct. 1998; 111(4):645-649.
Kurasawa et al., Arth & Rheum Nov. 2000 43(11):2455-2463.
Romer et al., J Invest Derm Dec. 2003 121(6):1306-1311.
Griffiths et al., Br J Dermatol Jun. 1991; 124(6):519-26.
Aggarwal and Gurney (2002)J. Leukocyte Biology71:1-8 “IL-17: prototype member of an emerging cytokine family”.
Aggarwal et al. (2003)J. Biol. Chem. 278:1910-1914 Interleukin-23 Promotes a Distance CD4 T Cell Activation State Characterized by the Production of Interleukin-17.
Blumberg et al. (2001)Cell104:9-19 “Interleukin 20: Discovery, Receptor Identification, and Role in Epidermal Function”.
Fossiez et al. (1996)J. Exp. Med. 183:2593-2603 “T Cell Interleukin-17 Induces Stromal Cells to Produce Proinflammatory and Hamatopoietic Cytokines”.
Ghoreschi et al. (2003)Nat Med9:40-46 “Interleukin-4 threapy of psoriasis Th2 responses and improves human autoimmune disease”.
Griffiths et al. (1991)Br J Dermatol. 124(6):519-526 “Modulation of leucocyte adhesion molecules, a T-cell chemotaxin (IL-8) and a regulatory cytokine (TNF-α) in allergic contact dermatitis (Rhus dermatitis)”.
Gudjonsson et al. (2004)Clin Exp Immunol. 135(1):1-8, Review “Immunopathogenic mechanisms in psoriasis”.
Kawaguchi et al. (2001)J. Immunol. 167:4430-4435 “Identification of a Novel Cytokine, ML-1, and Its Expression in Subjects with Asthma”.
Kawaguchi et al. (2004)J. Allergy Clin. Immunol. 114:1265-1273 “IL-17 cytokine family”.
Kennedy et al. (1996)J. Interferon Cytokine Res. 16:611-617 “Mouse IL-17: a cytokine preferntially expressed by alpha beta TCR+CD4-CD8-T cells”.
Kurasawa et al. (2000)Arth&Rheum. 43(11):2455-2463 “Increased Interleukin-17 Production in Patients with Systemic Sclerosis”.
Lee et al. (2004)J Exp Med199:125-130 “Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis vularis”.
Liao et al. (2002)J Immunol169:4288-4297 “IL-19 Induces Production of IL-6 and TNF-α”.
Liao et al. (2004)J Immunol. 173:6712-6718 “IL-19 Induced Th2 Cytokines and Was Up-Regulated in Asthma Patients”.
Nagalakshmi et al. (2004)Int Immunopharmacol4:577-592 “Expression patterns of IL-10 ligand and receptor gene families provide leads for biological characterization”.
Oppmann et al. (2000)Immunity13:715-725 “Novel p19 Protein Engages Il-12p40 to From a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12”.
Parrish-Novak (2002),J Biol Chem277: 47517-47523 “Interleukins 19, 20, and 24 Signal through Two Distinct Receptor Complexes”.
Romer et al. (2003)J Invest Dermatol6:1306-1311 “Epidermal Overexpression of Interleukin-19 and -20 mRNA in Psoriatic Skin Disappears After Short-Term Treatment with Cyclosporine A or Calcipotriol”,
Rouvier et al. (1993)J. Immunol. 150:5445-5456 “CTLA-8, Clones from an Activated T Cell, Bearing AU-Rich Messenger RNA Instability Sequences, and Homologous to a Herpesvirus Saimiri Gene”.
Starnes et al. (2001)J. Immunol. 167:4137-4140 “Cutting Edge: IL-17F, a Novel Cytokine Slectively Expressed in Activated T Cells and Monocytes, Regulates Angiogenesis and Endothelial Cell Cytokine Production”.
Teunissen et al. (1998)J. Invest. Derm. 111(4):645-649. Review “Interleukin0-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes”.
Witowski et al. (2004)Cellular and Molecular Life Sciences61(5):567-579 “Interleukin-17: a mediator of inflammatory respones”.
Wang et al. (2002)J. Biol Chem277:7341-7347 “Interleukin 24 (MDA-7/MOB-5) Signals through Two Heterodimeric Receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2”.
Wiekowski et al. (2001)J. Immunol. 166:7563-7570 “Ubiquitous Transgenic Expression of the Il-23 Subunit p19 Induces Multiorgan Inflammation, Runting, Infertility, and Premature Death”.
Yao et al. (1995)Immunity3:811-821 “Herpesvirus Saimiri Encodes a New Cytokine, IL-17, Which Binds to a Novel Cytokine Receptor”.
Chan Jason R.
Kastelein Robert A.
McClanahan Terrill K.
Murphy Erin
Nickol Gary
Schering Corporation
Schering-Plough Patent Department
Woodward Cherie M
LandOfFree
Method of evaluating inflammatory skin disorders using IL-17... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of evaluating inflammatory skin disorders using IL-17..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of evaluating inflammatory skin disorders using IL-17... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3911252